Spyre Therapeutics (SYRE) Stock Price, News & Analysis

Company Overview

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $16.65 to $17.39
• 50-Day Range: $14.68 to $17.81
• 52-Week Range: $10.91 to $40.26
• Volume: 298,692 shs
• Average Volume: 607,579 shs
• Market Capitalization: $1.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.40
• Consensus Rating: Buy

Spyre Therapeutics Stock Analysis - MarketRank™

Spyre Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 409th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Spyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Spyre Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Spyre Therapeutics are expected to grow in the coming year, from ($4.46) to ($3.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spyre Therapeutics is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spyre Therapeutics is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spyre Therapeutics has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.08% of the float of Spyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spyre Therapeutics has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Spyre Therapeutics has recently decreased by 5.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spyre Therapeutics does not currently pay a dividend.

Dividend Growth

Spyre Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

25.08% of the float of Spyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spyre Therapeutics has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Spyre Therapeutics has recently decreased by 5.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.33

News Sentiment

Spyre Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Spyre Therapeutics this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for SYRE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spyre Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.43% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYRE Stock Analysis - Frequently Asked Questions

How have SYRE shares performed this year?

Spyre Therapeutics' stock was trading at $23.28 at the beginning of 2025. Since then, SYRE shares have decreased by 28.2% and is now trading at $16.72.

How were Spyre Therapeutics' earnings last quarter?

Spyre Therapeutics, Inc. (NASDAQ:SYRE) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.24.

Who are Spyre Therapeutics' major shareholders?

Top institutional investors of Spyre Therapeutics include Perceptive Advisors LLC (2.53%), Jefferies Financial Group Inc. (2.30%), Geode Capital Management LLC (2.04%) and Franklin Resources Inc. (1.32%).
View institutional ownership trends.

How do I buy shares of Spyre Therapeutics?

Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Spyre Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYRE
• Previous Symbol: NASDAQ:SYRE
• CIK: 1636282
• Web: www.aeglea.com
• Phone: 512-942-2935
• Fax: 512-872-5121
• Employees: 73
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Spyre Therapeutics: $53.40
• High Price Target: $65.00
• Low Price Target: $27.00
• Potential Upside/Downside: +219.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$208.02 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.30%
• Return on Assets: -38.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.49
• Quick Ratio: 6.49

Sales & Book Value

• Annual Sales: $890 thousand
• Price / Sales: 1,134.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.97 per share
• Price / Book: 3.36

Miscellaneous

• Outstanding Shares: 60,400,000
• Free Float: 51,081,000
• Market Cap: $1.01 billion
• Optionable: Optionable
• Beta: 2.82